WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 5'1901 Infant (under 12 months) mortality rate: 202
GDP / capita (US$): 9'7381 Child (under 5 years) mortality rate: 232

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 15'492  15'246  15'001  14'756  14'512  12'533  10'124  7'909 
Births 328  327  327  327  326  318  304  275 
Surviving infants 322  321  321  320  320  309  289  254 
Pop. less than 5 years 1'594  1'591  1'592  1'590  1'589  1'503  1'407  1'218 
Pop. less than 15 years 4'691  4'667  4'643  4'617  4'590  4'329  3'863  3'304 
Female 15-49 years 4'054  3'991  3'927  3'863  3'798  3'245  2'504  1'835 

Number of reported case

(Click for retrospective incidence data for Ecuador)
Diphtheria 16 
Japanese encephalitis
Measles 72  263  1'646  2'722 
Mumps 799  733  1'331  837  626 
Pertussis 54  41  125  482  487  836 
Polio* 11 
Rubella 538 
Rubella (CRS)
Tetanus (neonatal) 88  28 
Tetanus (total) 15  28  169  81 
Yellow fever 12 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Ecuador)
Vaccine year result method % card seen                                                
BCG 2003  97  MCH   71.5  99*  99*  99*  99*  99*  99*  99  75 
DTP1          99*  99*  99*  99*  99*  99* 
DTP3 2003  75  MCH   71.5  99*  99*  99*  99*  99  88  75  10 
HepB_BD          16  57  40 
HepB3          99*  99*  99*  99*  99*  40 
Hib3          99*  99*  99*  99*  99 
JapEnc         
MCV 2003  66  MCH   71.5  99*  94  99*  99*  98  84  67  24 
MCV2          55  92  91  99 
PCV1          99*  99*  86  17 
PCV3          94  71  17 
Pol3 2003  72  MCH   71.5  99*  99*  99*  99*  99  84  77  19 
Rota1          99*  99*  99*  99*  99* 
Rota_last          99*  99*  99*  97  82 
Rubella1          99*  94  99*  99*  98 
TT2plus 1988  48  MCH     75  75  70  74  70  31 
PAB         
VAD1          45  99*  84 
YFV          89  89  96  99*  99*  28 
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Ecuador)
BCG 99  99  99  99  99  99  89  76 
DTP1 99  99  99  99  99  93  87  31 
DTP3 99  99  99  99  99  88  68  10 
HepB3 98  98  98  98  98  38 
Hib3 99  99  99  99  99 
MCV 94  94  95  97  98  99  60  24 
PAB 85  85  74  73  73  42  82 
PCV3 94  71  17 
Pol3 99  99  99  99  99  84  67  19 
Rota_last 97  97  97  97  82 
YFV 58  58  65 

Number of districts in the country 220  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90%
From 80 to 89%
From 50 to 79%
Less than 50%
Proportion of districts
not reporting DTP3 coverage
100
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DT 5 years; Yes
DTwP 12-23 months; Yes
DTwPHibHep 2, 4, 6 months; Yes
HepB birth; Yes At risk groups and children at 11 years
Influenza 6 months to 5 years; 18-23 years; > =65 years; Yes
MMR 1, 6 years; Yes
MR 6-12 months; Yes
MenBC Yes risk groups
OPV 2, 4, 6, 18 months; Yes
Pneumo_conj 2, 4, 12 months; Yes
Pneumo_ps 65 years; Yes and risk groups
Rotavirus 2, 4 months; Yes
Td Yes CBAW
Varicella 12-23 months; 6, 10 years; Yes
VitaminA >1 year; 12 to 50 months; Yes
YF 12-23 months; Yes every 10 years in Amazon

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR Yes  Yes  Yes  No  Yes  No  Yes 
What years does the MYP cover? number 2011 -2016  2011-2015  4 years        5 años 
Nº of districts with microplans that include activities to raise immunization coverage number 76  24  80  24  170    53 

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR Yes  Yes  Yes         

System performance

Total number of districts in country number 220  171  170  210  170  169  167 
Nº districts with DTP3 coverage >=80% number   142  146  151  135  131  129 
% of districts with DTP3 coverage >=80% From 0 to 100%   83  86  72  79  78  77 
Nº districts with measles (MCV1) coverage >=95% number NA  66  112  116  80     
% of districts with MCV1 coverage >=95% From 0 to 100%   39  66  55  47     

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes         

Finance

Percentage of routine vaccines funded by Government From 0 to 100% 100  100  100  100  100  100  100 

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.